

ASX RELEASE (29 MAY 2020)

THC Global establishes presence in growing CBD market

Investment Highlights:

- THC Global's Australian-produced full-spectrum CBD medicine has now been prescribed for Australian patients
- CBD product range to be expanded within weeks to provide Schedule 4 high purity option for prescribers and patients
- TGA scheduling review may see low-dose Schedule 3 CBD medicines in pharmacies by early 2021
- THC Global well-positioned for exponential growth in CBD product demand
- THC Global's CanndeoCare team provided a scheduling review submission to support a transition to safe and appropriate supply of low-dose CBD medicines

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) is pleased to confirm that the Company's first Australian-produced medicinal cannabis product has been prescribed to an Australian patient, marking a new milestone for the wholly Australian sourced and produced cannabis medicine.

The first product is a full-spectrum cannabidiol (CBD) medicine. Full-spectrum medicines are highly sought after by both patients and prescribers as they include minor cannabinoids, terpenes and flavonoids that may provide different therapeutic outcomes for patients than CBD medicine formulated from isolate.

In the coming weeks, THC Global will additionally make available CBD medicine produced from isolate, which conforms to Schedule 4 requirements of high purity CBD. Manufacture of the isolate and the Schedule 4 medicine will occur in THC Global's large-scale pharmaceutical GMP facility in Southport.

A review of scheduling for low-dose CBD, to be considered at the Australian Therapeutic Goods Administration Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (ACMS/ACCS) meetings in June 2020, may result in some CBD medicines being reclassified to the lower, Schedule 3. This would enable low-dose pharmaceutical-grade CBD to be purchased at pharmacies without a prescription by early 2021. This will result in exponential growth in demand for pharmaceutical CBD products.

THC Global is exceptionally well positioned for an expanding market in CBD. THC Pharma, the Company's wholly owned subsidiary, can manufacture cannabis medicines at its Southport facility at global scale. The capacity to manufacture cannabis-sourced medicines for hundreds of thousands of patients on an ongoing basis is matched with highly scalable sources of biomass from its own facilities, from additional local cannabis growers and from imported raw crude extract.

THC Global's CanndeoCare team, recognising the priority of consumer safety in any rescheduling decision, submitted a detailed dossier to the Joint ACMS/ACCS meeting. The Company has highlighted its support of Schedule 3 availability for naturally sourced CBD, noting its well-documented safety profile. CanndeoCare provided further opinion on the presence of minor cannabinoids in the medicines and appropriate package warnings, leveraging its extensive body of cannabis medicine research and knowledge.

THC Global CEO, Ken Charteris said: "We are pleased that THC Global is helping Australia's patients through its wholly Australian sourced CBD medicine, and we look forward to expanding the range of CBD medicines available for doctors and prescribers. Australians may soon have access to CBD medicines without prescription at pharmacies, and we look forward to these developments being progressed safely and responsibly. THC Global remains Australia's best-placed company for providing Schedule 3 CBD medicines at scale."

For further information, please contact:



Ken Charteris
Chief Executive Officer
e: ceo@thc.global

Sonny Didugu & Jarrod White
Joint Company Secretaries
e: corporate@thc.global
p: +61 2 8088 4760

The Capital Network
Julia Maguire
e: julia@thecapitalnetwork.com.au
p: + 61 2 8999 3699

ASX release authorised by THC Global's Management Committee – the Chairman, Deputy Chairman, and CEO.

THC Global Group Limited (ASX: THC) thc.global

THC Global is a diversified global cannabis company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia's cannabis regulations. THC Global's Southport Facility is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates Crystal Mountain, a fast growing hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sector in North America and Europe.

For prospective patients or healthcare professionals seeking more information on medicinal cannabis, please visit: canndeocare.com and tetrahealth.com.au.